← Eichor
Study identifier: NCT06765252 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients

Condition: Colorectal Cancer · Breast Cancer  ·  Sponsor: Ain Shams University

PhaseN/A
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.

This description comes directly from the study's public registry record.

Talk to the study team

Raghad Nassar, Teaching Assistant  ·  01004446077  ·  raghad.essam22@pharma.asu.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Clinical Oncology, Faculty of Medicine, Menoufia UniversityShibīn al Kawm, Menoufia, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06765252